Innovent Biologics Inc
Change company Symbol lookup
Select an option...
IVBXF Innovent Biologics Inc
SDGR Schrodinger Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc
HIIIU Hudson Executive Investment Corp III
PMVP PMV Pharmaceuticals Inc
Go


Based in China
Company profile

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Closing Price
$3.73
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.73
Day's Low
3.73
Volume
(Heavy Day)
Volume:
100

10-day average volume:
100
100

Company Profile

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
7.25x
Price/Book (MRQ)
3.31x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

No short interest available.

Share Information

IVBXF is in a share class of common stock
Float
1.4B
Shares Outstanding
1.5B
Institutions Holding Shares
--
--

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.